AstraZeneca (NYSE:AZN) is commonly recognized as one of the most fragile Big Pharma stocks on the market. While its peers, such as GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE), have restructured their R&D strategies or spun out divisions, AstraZeneca has only recently started to make changes. Last autumn, the company suspended its share-buyback program in an effort to preserve cash, reshuffled its management team, and today announced its boldest move yet: It's moving its headquarters and shifting focus to three primary R&D sites. In the following video, Motley Fool analyst Max Macaluso discusses why investors should take notice of the company's bold plans.
Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.